Share Purchase Plan Offer Documents
Released
Released
Announcement PDF
Share Purchase Plan – Offer Documents
Melbourne, Australia; 16 December 2015: Starpharma Holdings Limited (ASX:SPL,
OTCQX:SPHRY) is pleased to attach documentation regarding its Share Purchase Plan
(SPP).
Australian and New Zealand registered shareholders who held shares at 7pm
(Melbourne time) on the record date of 8 December 2015 are eligible to participate in
the SPP.
The SPP opens today, 16 December 2015, and will close at 5pm (Melbourne time)
on Friday 15 January 2016 (unless extended).
All eligible (Australian-based) directors intend to participate in the SPP.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a
world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular
in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development
programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products
internally and others via commercial partnerships.
Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has
antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval
for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of
recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto
Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for
purchase in Australia under Ansell’s Lifestyles® Dual ProtectTM brand. Ansell manufactures and sells leading condom brands
worldwide, including LifeStyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the
world’s second largest condom market.
In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of
dendrimer-enhanced, or DEPTM versions of existing drugs are under development. The most advanced of these is DEPTM
docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid
tumours. In preclinical studies DEPTM docetaxel has shown significant tumour-targeting and superior anti-cancer effects
across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere®
(docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEPTM drug delivery platform
in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds
directed at a defined family of targets.
In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama
(formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient
in Roundup®). For more information please visit: www.starpharma.com
Media:
Buchan Consulting
Gabriella Hold
Tel: +61 3 9866 4722
ghold@buchanwe.com.au
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Starpharma:
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”,
“targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or
similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of
product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding
any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for
sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval
and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain
or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial
results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is
providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments or otherwise.
Page 2 of 2
Starpharma Holdings Limited
A.B.N. 20 078 532 180
4-6 Southampton Crescent
Abbotsford Victoria 3067 Australia
www.starpharma.com
000
SPL
MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000
16 December 2015
Dear Shareholder,
2015/16 Share Purchase Plan
Following the successful capital raising of A$32 million through a placement to existing
and new institutional, sophisticated and professional investors (Placement), the Board
of Directors of Starpharma Holdings Limited (Starpharma) is pleased to offer eligible
shareholders the opportunity to subscribe for new ordinary shares in Starpharma by way
of a share purchase plan (SPP).
The offer price under the SPP is A$0.73 per share, the same issue price as the shares
issued under the Placement.
The Placement was significantly oversubscribed with strong participation from new and
existing institutions including large global funds and domestic funds. The Placement also
brought 9 new institutional investors onto the register, including a major domestic fund.
The funds raised will support advancement in all areas of the business, including the
DEPTM docetaxel Phase 2 clinical program and the acceleration of further DEPTM drug
delivery candidates into the clinic. The funds will also support the licensing, approvals and
launches of the VivaGel® BV symptomatic relief product, and the completion of the Phase 3
trials of VivaGel® for prevention of recurrent bacterial vaginosis (BV) which are well advanced.
This capital raising also strongly positions the company to accelerate various programs
to capture the growing partner interest in our portfolio by global pharmaceutical and
healthcare companies and it follows the recent licensing agreement with AstraZeneca in
the DEPTM platform.
208214_01SQ0B
*L000001*
T 000001
916CR_0_Sample_CA/000001/000001
As set out in our ASX announcement on 9 December 2015, the proceeds of up to $35 million
(before costs) from the Placement and SPP will fund advancement across all areas of the
business including:
Activity
Phase 2 clinical program for DEP® docetaxel
Accelerate further DEP® drug delivery candidates into preclinical and Phase 1 trials
Commercialisation of VivaGel® BV for symptomatic relief and the VivaGel® condom,
including product and launch working capital
Complete Phase 3 trials of VivaGel® for prevention of recurrence of BV
Commercialisation of agrochemical products
Provide working capital and strengthen the balance sheet to support commercial
negotiations underway for various products
Under the SPP, you can subscribe for up to A$15,000 worth of new Starpharma ordinary
shares without paying any brokerage. The SPP will be capped at A$3 million and Starpharma
will scale back Applications if they exceed A$3 million in aggregate. If Applications are scaled
back, Starpharma reserves the right to undertake the scale back in any manner it considers fit.
Australian and New Zealand registered shareholders who held shares at 7:00pm (Melbourne
time) on the record date of 8 December 2015 are eligible to participate in the SPP. The SPP
closes at 5:00pm (Melbourne time) on 15 January 2016 (unless extended).
The Board encourages you to carefully read the enclosed SPP offer document and
application form, before making your investment decision.
On behalf of the Board, I thank you for your continued support as a Starpharma shareholder.
Yours sincerely,
208214_01SQ0B
Rob Thomas AM
Chairman
Starpharma Holdings Limited
2015/16 Share Purchase Plan
Starpharma Holdings Limited ACN 078 532 180 (Starpharma) is pleased to provide Eligible
Shareholders (see section 6 below) with the opportunity to participate in Starpharma’s 2015/16
Share Purchase Plan (SPP) by subscribing for up to $15,000 of new fully paid ordinary shares
(New Shares) in Starpharma (Offer).
The price of each New Share is $0.73.
Details of the Offer and how to participate are set out in this Offer Document.
You may contact Starpharma’s shareholder information line, on 1300 782 534 (within Australia) or
+61 3 9415 4164 (outside Australia) if you have any queries in relation to the SPP.
1.
Background
On 9 December 2015, Starpharma announced that it had completed a placement of Shares to
international and domestic institutional, sophisticated and professional investors to raise $32 million
at $0.73 per Share (Placement).
At the same time as it announced the Placement, Starpharma announced that it would raise up to
an additional $3.0 million through the issue of approximately 4.1 million New Shares to Eligible
Shareholders under an SPP priced at $0.73 per New Share, the same issue price as that offered
under the Placement.
For current information on Starpharma, shareholders are referred to the 2015 Annual Report and to
recent announcements lodged with ASX. These documents can be found on Starpharma’s website
at www.starpharma.com or on the ASX website at www.asx.com.au (ASX code: SPL).
2.
Key Dates
Key dates for the SPP are as follows:
Indicative Timetable*
Record Date
7:00pm (Melbourne time), 8 December 2015
Opening Date
16 December 2015
Closing Date
5:00pm (Melbourne time), 15 January 2016 (unless extended)
Allotment of New Shares
22 January 2016
Trading of New Shares expected
to commence on ASX
25 January 2016
Holding statements expected to
be dispatched to shareholders
28 January 2016
* These dates are indicative only and subject to change. Starpharma reserves the right to amend this indicative timetable
without notice. In particular, Starpharma reserves the right, subject to the Corporations Act and the Listing Rules, to close
the Offer early, to extend the Closing Date or to withdraw the Offer without prior notice. Any extension of the Closing Date
will have a consequential effect on the date for the issue of New Shares.
3.
Price and allocation
The price payable for each New Share under the SPP will be $0.73, being the price at which
Shares were issued under the Placement. This represented a 7.9% discount to the volume
weighted average market price of Shares traded in the ordinary course on ASX over the last 5 days
on which sales of Shares were recorded before the day on which the Placement and SPP were
announced.
The Offer under the SPP is being made in accordance with the disclosure relief granted by ASIC
under CO 09/425. Under CO 09/425, the maximum value of New Shares each Eligible Shareholder
may subscribe for is $15,000.
Under the SPP, you may apply for a parcel of New Shares in the amount of $1,000, $2,500,
$5,000, $7,500, $10,000, $12,500 or $15,000. Starpharma will deal with Applications that are not
made in these amounts in accordance with section 8.2.
In the absence of a scale back (see section 7), the number of New Shares to be issued to you will
be calculated by dividing your Application amount by the offer price of $0.73, then rounding up to
the nearest whole number of New Shares.
Accordingly, the number of New Shares that will be issued for each Application amount are as
follows:
Application Amount
New Shares
$1,000
1,370
$2,500
3,425
$5,000
6,850
$7,500
10,274
$10,000
13,699
$12,500
17,124
$15,000
20,548
Eligible Shareholders will not be obliged to pay brokerage or other fees in respect of New Shares
acquired under the SPP (although Starpharma will pay certain professional and other fees to third
parties). The SPP provides an opportunity for all Eligible Shareholders to increase their
shareholding in a low cost way.
4.
Use of funds and effect of the Offer
As set out in our ASX announcement on 9 December 2015, the proceeds of up to $35 million
(before costs) from the Placement and SPP will fund advancement across all areas of the business
including:
Activity
1. Phase 2 clinical program for DEPTM docetaxel
2. Accelerate further DEP® drug delivery candidates into preclinical and Phase 1 trials
3. Commercialisation of VivaGel® BV for symptomatic relief and the VivaGel® condom,
including product and launch working capital
4. Complete Phase 3 trials of VivaGel® for prevention of recurrence of BV
5. Commercialisation of Agrochemical products
6. Provide working capital and strengthen balance sheet to support commercial negotiations
underway for various products.
The effect of the Offer will be to increase the number of Shares on issue and increase the cash
held by Starpharma, the extent of which will depend on Applications received for New Shares.
Starpharma has not set a minimum amount to be raised under the SPP and it is not underwritten.
5.
Participation is optional
Participation in the SPP is entirely optional (subject to the eligibility criteria set out in section 6).
The Offer to acquire New Shares under the SPP is not a recommendation. If you are in any doubt
about this Offer, including whether you should participate in the SPP or how such participation will
affect you, you should consider seeking independent financial and taxation advice before making a
decision as to whether or not to accept this Offer.
You should be aware that the price you pay for New Shares under the SPP may either be higher or
lower than the market price of Starpharma Shares on the date New Shares are allotted and issued
to you under the SPP. This means that the market value of the New Shares when they are issued
to you may be less than the price you paid for them.
Starpharma recommends that you monitor the Share price, which can be found in the financial
pages of major Australian metropolitan newspapers, or on the ASX website at www.asx.com.au
(ASX code: SPL).
6.
The Offer and eligibility
A person will be eligible to participate in the Offer (an Eligible Shareholder) if:
(1)
the person was a registered holder of Shares at 7:00pm (Melbourne time) on 8 December
2015 (Record Date); and
(2)
the person’s registered address is in Australia or New Zealand.
Starpharma has determined that it is not practical for holders of Shares with registered addresses
in other jurisdictions to participate in the SPP. To the extent that a person holds Shares on behalf
of another person resident outside Australia or New Zealand, it is that person’s responsibility to
ensure that any acceptance complies with all applicable foreign laws.
The New Shares to be issued under this SPP have not been and will not be registered under the
Securities Act, or the securities laws of any state or other jurisdiction of the United States. In order
to comply with relevant securities laws, the New Shares to be issued under this SPP may not be
offered to shareholders located in the United States or to shareholders who are, or who are acting
for the account or benefit of, U.S. Persons.
Accordingly, you must not send copies of this Offer Document or any other material relating to the
SPP to any person resident in the United States or who is, or is acting for the account or benefit of,
U.S. Persons. You may not submit any completed Application Forms for any person resident in the
United States or who is, or is acting for the account or benefit of, U.S. Persons. Failure to comply
with these restrictions may result in violations of applicable securities laws.
7.
Scale-back and shortfall
The SPP will be capped at $3.0 million and Starpharma will scale back Applications if they exceed
$3.0 million in aggregate. If Applications are scaled back, Starpharma reserves the right to
undertake the scale back in any manner it considers fit.
If Starpharma exercises its right to scale back Applications, the amount of your Application as
scaled back may not be equal to a whole number of New Shares. In that event, the number of New
Shares allotted to you will be rounded up to the nearest whole number of New Shares. The
difference in Application Monies will be refunded by Starpharma, without interest, as soon as
practicable after the New Shares are issued.
The Board reserves the right to place any shortfall under the SPP at its discretion.
8.
Applications
8.1
Method of Application
An Eligible Shareholder may apply for New Shares by either:
(1)
completing the attached Application Form and returning it to:
Starpharma 2015/16 Share Purchase Plan
Computershare Investor Services Pty Limited
GPO Box 505
Melbourne Victoria 3001
AUSTRALIA
together with a cheque, bank draft or money order made payable to “Starpharma
Holdings Ltd – 2015/16 SPP” for the appropriate Application Monies by no later
than 5.00pm (Melbourne time) on the Closing Date; or
(2)
making a BPAY® payment by using the specific Biller Code and unique Customer
Reference Number (CRN) shown on your Application Form.
If you make your payment using BPAY®, you do not need to return your Application
Form. Payment must be received by no later than 5.00pm (Melbourne time) on
the Closing Date.
You should be aware that your own financial institution may implement earlier cutoff times with regard to electronic payment, and you should therefore take this into
consideration when making payment.
It is your responsibility to ensure that funds submitted through BPAY® are received
by 5.00 pm (Melbourne time) on the Closing Date.
Starpharma may, but is not obliged to, accept Applications received after the Closing Date.
If Starpharma does not accept an Application for any reason, Starpharma will refund any
excess Application Monies to the Eligible Shareholder, without interest, as soon as
practicable after the New Shares are issued.
8.2
Application amounts
Applications may only be made for parcels of New Shares in the amounts listed in section 3
and on the Application Form. If the amount of the cheque, bank draft or money order
tendered with your Application Form or paid via BPAY® is:
8.3
(1)
less than $1,000, Starpharma will not allot any New Shares to you and will refund
your Application Monies;
(2)
greater than $15,000, subject to scale back, Starpharma will allot the maximum
number of New Shares to you and will refund your excess Application Monies; or
(3)
for an amount between $1,000 and $15,000 that is not one of the designated
Application amounts, subject to scale back, Starpharma will allot to you the number
of New Shares that would have been allotted to you had you applied for the highest
designated amount that is less than the amount of your cheque, bank draft, money
order or your BPAY® payment, and will refund your excess Application Monies.
Non-renounceable
Each Offer is non-renounceable. An Eligible Shareholder may not transfer or otherwise
deal with its right to apply for New Shares under the SPP.
8.4
One offer per shareholder
Subject to section 8.6, an Eligible Shareholder is entitled to apply under one (and only one)
Offer. Starpharma may refuse to accept any Application which Starpharma, or a person
maintaining the register of members (Register) on behalf of Starpharma, believes will
result in a person being issued New Shares under more than one Offer.
If you are recorded with one or more persons as the joint holder of a holding of Shares, that
joint holding is considered to be a single registered holding for the purpose of the SPP.
Joint holders are only entitled to participate in the SPP in respect of that single holding. If
the same joint holders receive more than one Offer due to multiple holdings, the joint
holders may only apply under one Offer.
8.5
Certification by Eligible Shareholders
By applying for New Shares under the Offer, each Eligible Shareholder certifies that the
aggregate of the application price paid by it for:
(1)
New Shares the subject of this Offer; and
(2)
any other Shares applied for, or which the Eligible Shareholder has instructed a
custodian, trustee or nominee to acquire on their behalf, under the SPP or any
similar arrangement offered by Starpharma in the 12 months prior to the date of its
Application,
does not exceed $15,000.
The $15,000 limit applies irrespective of the number of Shares the Eligible Shareholder
holds on the Record Date. Starpharma reserves the right to reject any Application for New
Shares under this SPP to the extent it considers that the Application (whether alone or in
conjunction with other Applications) does not comply with these requirements.
8.6
Applications by custodians, trustees and nominees
A custodian, trustee or nominee within the definition of “custodian” in CO 09/425
(Custodian) who holds Shares on account of one or more Eligible Shareholders
(Beneficiaries) may apply for New Shares up to a maximum of $15,000 worth of New
Shares for each Beneficiary, provided that it certifies to Starpharma in writing the matters
set out in condition 9 of CO 09/425. This certification has been incorporated in the
Custodian Application Form prepared by our Share Registry.
Custodians should have received a Custodian Application Form via email from the Share
Registry. Please contact Starpharma’s shareholder information line on 1300 782 534
(within Australia) or +61 3 9415 4164 (outside Australia) if you are a Custodian and have
not received a Custodian Application Form.
Custodians who wish to apply for New Shares on behalf of one or more Beneficiaries must,
by no later than 5.00pm (Melbourne time) on the Closing Date, complete a Custodian
Application Form and submit it via email to custodians@computershare.com.au (in MS
excel format) and then return their original signed Custodian Application Form to:
Starpharma 2015/16 Share Purchase Plan
Computershare Investor Services Pty Limited
GPO Box 505
Melbourne Victoria 3001
AUSTRALIA
Payment by Custodians must be received by no later than 5.00pm (Melbourne time) on
the Closing Date by the Custodian either:
(1)
returning a cheque, bank draft or money order made payable to “Starpharma
Holdings Ltd – 2015/16 SPP” with the Custodian Application Form; or
(2)
making a BPAY® payment using the specific Biller Code and unique Customer
Reference Number (CRN) shown on the Application Form enclosed with this Offer
Document (and in the manner described in section 8.1(2)).
If a person holds Shares as a trustee or nominee for another person, but is not a Custodian
for the purposes of CO 09/425, you cannot participate for a Beneficiary in the manner
described above. In this case, the rules for multiple single holdings set out in section 8.4
apply.
By applying for Shares on behalf of a Beneficiary, the Custodian warrants to Starpharma
that it has the authority of the Beneficiary to do so. For the purposes of section 6(2), the
relevant address for determining an Eligible Shareholder is the address of the Custodian.
To the extent that a Custodian or a person holds shares on behalf of another person
resident outside Australia or New Zealand, it is the Custodian’s responsibility to ensure that
any acceptance complies with all applicable foreign laws.
9.
Effect of Application
By applying for New Shares under an Offer, an Eligible Shareholder is taken to:
(1)
agree to be bound by the terms and conditions set out in this Offer Document, the Offer
and the Application Form;
(2)
authorise Starpharma to place the Eligible Shareholder’s name on Starpharma’s Register
in respect of those New Shares;
(3)
agree to be bound by Starpharma’s constitution; and
(4)
provide the certification referred to in section 8.5 and, where applicable, the warranty in
section 8.6.
10.
Rights attaching to New Shares
New Shares issued under the SPP will rank equally with all existing Shares and will carry the same
voting rights, dividend rights and other entitlements at the date they are issued.
The New Shares are expected to be allotted under the SPP on 22 January 2016. Starpharma
expects that the New Shares will be listed for quotation on ASX on 25 January 2016 and holding
statements or issue notices in respect of the New Shares allotted under the SPP will be dispatched
on 28 January 2016.
You should confirm your holding before trading in any New Shares you believe have been issued
to you under the SPP. Any shareholder that sells New Shares before receiving confirmation of
their holding in the form of their holding statement will do so at their own risk. Starpharma and the
Share Registry disclaim all liability whether in negligence or otherwise (and to the maximum extent
permitted by law) to persons who trade their New Shares before receiving their holding statements,
whether on the basis of confirmation of the allocation provided by Starpharma or the Share
Registry.
11.
Alteration of terms
Starpharma may, in its discretion, vary, suspend or cancel the Offer at any time, subject to the
Corporations Act, ASIC Class Orders, the Listing Rules and any other law or regulation to which
Starpharma is subject.
A variation, suspension or cancellation does not give rise to any liability on the part of, or any action
against, Starpharma or any member of the Board.
If the Board determines to suspend or cancel the SPP during the currency of an Offer, any
application money received by Starpharma will be refunded to the Eligible Shareholder, without
interest, as soon as practicable after the suspension or cancellation.
12.
Offer document
In the absence of an exemption in the Corporations Act, ASIC class order or other ASIC relief, a
person may not offer shares without lodging a disclosure document with ASIC.
ASIC has granted relief from the disclosure requirements in the Corporations Act under CO 09/425
for shares offered under a share purchase plan. This Offer meets the requirements of CO 09/425.
13.
General
Starpharma may settle in any manner it thinks fit, any difficulties, anomalies or disputes which may
arise in connection with or by reason of the operation of the SPP or the Offer and the decision of
Starpharma will be conclusive and binding on all participants and other persons to whom the
determination relates.
14.
Definitions
Terms and abbreviations used in this Offer Document have the following meaning:
$
Australian dollars
Application
A valid application made in accordance with section 8.1
Application Form
The application form attached to this Offer Document
Application Monies
Monies paid by Eligible Shareholders in respect of New Shares
applied for under the SPP
ASIC
Australian Securities and Investments Commission
ASX
ASX Limited ABN 98 008 624 691
Board
The board of directors of Starpharma
Business day
Has the meaning given to that term in the Listing Rules
Closing Date
5:00pm (Melbourne time), 15 January 2016 (unless extended)
CO 09/425
ASIC Class Order CO 09/425 Share and interest purchase plans
Constitution
The constitution of Starpharma as amended from time to time
Corporations Act
Corporations Act 2001 (Cth)
Corporations Regulations
Corporations Regulations 2001 (Cth)
Eligible Shareholder
A person who meets the requirements of section 6
Listing Rules
The ASX Listing Rules
New Share
A Share to be issued pursuant to the Offer
Offer
The offer of New Shares under this Offer Document
Securities Act
Securities Act of 1933 of the USA
Share
A fully paid ordinary share in Starpharma
Share Registry
Computershare Investor Services Pty Limited
US Person
Has the meaning given to that term in Regulation S of the
Securities Act
United States
Has the meaning given to that term in Regulation S of the
Securities Act
For all enquiries:
*S000001Q01*
Phone:
(within Australia) 1300 782 534
(outside Australia) 61 3 9415 4164
Web:
www.investorcentre.com/contact
T 000001
000
SPL
MR SAM SAMPLE
123 SAMPLE STREET
SAMPLETOWN VIC 3000
Make your payment:
See overleaf for details of the Offer and
how to make your payment
Share Purchase Plan Application Form
Your payment must be received by 5:00pm (Melbourne time), 15 January 2016
This is an important document that requires your immediate
attention.
It can only be used in relation to the shareholding represented by
the details printed overleaf. If you are in doubt about how to deal
with this form, please contact your financial or other professional
adviser.
By making payment you agree to be bound by the Constitution of
Starpharma Holdings Limited and that the submission of this
payment constitutes an irrevocable offer by you to subscribe for
Starpharma Holdings Limited shares on the terms of
Share your feedback
Discover